All In Biotech

Investigational drug · Phase 3

Cemdisiran

Also called: ALN-CC5

Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Paroxysmal Nocturnal Hemoglobinuria, Generalized Myasthenia Gravis, Age-related Macular Degeneration (AMD).

Phase 3

Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

5

4 still active

All registered trials

14

Any phase or sponsor naming "Cemdisiran"

First trial start

2021

Dec 14, 2021

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Cemdisiran", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Paroxysmal Nocturnal Hemoglobinuria
  • Generalized Myasthenia Gravis
  • Age-related Macular Degeneration (AMD)
  • Geographic Atrophy (GA)

Approved drugs for the same conditions: Paroxysmal nocturnal hemoglobinuria · Myasthenia gravis · Wet macular degeneration · Geographic atrophy · Neurology · Ophthalmology

Largest trials

Live from ClinicalTrials.gov: studies naming "Cemdisiran" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 21 on PubMed

Also in development for Paroxysmal Nocturnal Hemoglobinuria

  • HRS-5965Phase 36 trials

    Chengdu Suncadia Medicine Co., Ltd. · Primary IgA Nephropathy, Paroxysmal Nocturnal Hemoglobinuria

  • HSK39297Phase 35 trials

    Haisco Pharmaceutical Group Co., Ltd. · IgA Nephropathy (IgAN), Paroxysmal Nocturnal Hemoglobinuria, Paroxysmal Nocturnal Haemoglobinuria (PNH)

  • MY008211APhase 35 trials

    Wuhan Createrna Science and Technology Co., Ltd · Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Nocturnal Hemoglobinuria, IgA Nephropathy (IgAN)

  • FXS6837Phase 34 trials

    Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · Paroxysmal Nocturnal Hemoglobinuria, Primary IgAN, IgAN

  • NTQ5082Phase 34 trials

    Nanjing Chia-tai Tianqing Pharmaceutical · Paroxysmal Nocturnal Hemoglobinuria, Primary IgA Nephropathy

  • NM8074Phase 28 trials

    NovelMed Therapeutics · Paroxysmal Nocturnal Hemoglobinuria, Dermatomyositis, PNH - Paroxysmal Nocturnal Hemoglobinuria

  • LP-005Phase 24 trials

    Longbio Pharma · Periodontitis, Paroxysmal Nocturnal Hemoglobinuria, Complement-mediated Renal Diseases

  • HS-10542Phase 22 trials

    Jiangsu Hansoh Pharmaceutical Co., Ltd. · IgAN, Immunoglobulin A Nephropathy (IgAN), Glomerular Disease

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Regeneron.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.